Evidence map›Paper›PMID 41542816›Full record

ReviewMolecular oncology2026

European Code Against Cancer, 5th edition - cancer-causing infections and related interventions.

Catharina Johanna Alberts, Paul Bloem, Silvia de Sanjosé, Sophie Grabar, Marcis Leja, Peter Malfertheiner, Mojca Matičič, Francis Mégraud, Francesco Negro, Martyn Plummer and 9 more

Abstract readReview
In one paragraph

Review in Molecular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Catharina Johanna AlbertsDepartment of Infectious Diseases, Public Health Service (GGD), Amsterdam, The Netherlands.ORCID 0000-0002-5604-3689
Paul BloemWorld Health Organization, Geneva, Switzerland.
Silvia de SanjoséISGlobal, Barcelona, Spain.
Sophie GrabarSorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Assistance Publique-Hopitaux de Paris, Hôpital St Antoine, Paris, France.
Marcis LejaInstitute of Clinical and Preventive Medicine, University of Latvia, Riga, Latvia.
Peter MalfertheinerMedical Department II, University Clinic, Ludwig Maximilian University, München, Germany.
Mojca MatičičClinic for Infectious Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Francis MégraudINSERM U1312 BRIC, University of Bordeaux, France.
Francesco NegroUniversity Hospitals of Geneva, Switzerland.
Martyn PlummerUniversity of Warwick, UK.
Maarten Schim van der LoeffDepartment of Infectious Diseases, Public Health Service (GGD), Amsterdam, The Netherlands.
Graciela BalbínIberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
Josefina SalazarIberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
Hajo ZeebLeibniz-Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany.
Ariadna FeliuEnvironmental and Lifestyle Epidemiology Branch, International Agency for Research on Cancer, Lyon, France.ORCID 0000-0002-0033-9026
Erica D'SouzaEnvironmental and Lifestyle Epidemiology Branch, International Agency for Research on Cancer, Lyon, France.
David RitchieEnvironmental and Lifestyle Epidemiology Branch, International Agency for Research on Cancer, Lyon, France.ORCID 0000-0003-4816-113X
Carolina EspinaEnvironmental and Lifestyle Epidemiology Branch, International Agency for Research on Cancer, Lyon, France.ORCID 0000-0001-6848-4687
Silvia FranceschiCentro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.ORCID 0000-0003-4181-8071

Funding

European Union from the EU4Health 101075240World Health Organization 001
6 · The paper itself

Abstract

The main infections that cause cancer in the European Union (EU) are Helicobacter pylori (H. pylori), human papillomavirus (HPV), hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Altogether, in 2022, these infections accounted for ~ 5% of all cancers in the EU, mainly of the stomach, cervix uteri and liver. The largest burden of infection-caused cancers was found in the south of the EU and near the eastern border. Substantial progress in the efficacy of interventions against these infections has been made since the release of the 4th edition of the European Code Against Cancer in 2015. Cancers due to infections can increasingly be prevented by prophylactic vaccines (HPV and HBV) and/or prompt diagnosis and treatment that can either cure (HCV and H. pylori) or slow down the infection (HBV and HIV), thus substantially reducing disease risk. Tools to tackle carcinogenic infections are also increasingly accessible and affordable in the EU, but their implementation is slow. Public awareness, political will and cost-effective protocols are necessary to establish large programmes of vaccination or testing and treatment. Progress monitoring, as well as avoiding disinformation and stigma, is crucial to ensure that advances in medical progress are fully leveraged. The recently published 5th edition of the European Code Against Cancer therefore recommends: (1) vaccinate girls and boys against HBV and HPV at the age recommended in your country; (2) take part in testing and treatment for HBV and HCV, HIV and H. pylori, as recommended in your country.

Indexed as

NeoplasmsEuropean UnionHelicobacter InfectionsHepatitis BHepatitis CHumanscancerEuropean Code Against Cancer(HBV and HIV)Helicobacter pylorihepatitis B virushepatitis C virushuman immunodeficiency virushuman papillomavirus

Identifiers

PMID41542816
PMCPMC12809466

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.